GENB Generate Biomedicines, Inc. - Common Stock
NASDAQ · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 6, 2026
$13.69
· of 52w range
· above low
· to high
$11.1052w low
$22.6752w high
Market Cap (MRQ)
$1.76B
your badges
52W Range
$11–$23
Analyst Rating
BUY
Price Target
$27
P/E
·
ROE
·
Net Profit Margin
·
Your badge strip is empty — pin a metric anywhere on this page.
GENB Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$13.69
Market Cap (MRQ)
$1.76B
52W Range
$11–$23
GENB Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
10-Year Performance Revenue, net income, margins and EPS trends
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | GENB | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/B (MRQ) | 3.9 | · | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | GENB | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 8.3 | · | · | · |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-55.3%
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | $-0.52 | $-0.51 | -2.8% | |
| March 31, 2026 | $-1.06 | $-0.51 | -107.8% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Balance Sheet
| Metric | Trend | 2025 |
|---|---|---|
| Cash & Equivalents | $122M | |
| Short-term Investments | $100M | |
| Prepaid Expense | $13M | |
| Current Assets | $234M | |
| PP&E (Net) | $29M | |
| PP&E (Gross) | $77M | |
| Accum. Depreciation | $48M | |
| Other Non-current Assets | $7M | |
| Total Assets | $330M | |
| Accounts Payable | $4M | |
| Current Liabilities | $82M | |
| Capital Leases | $51M | |
| Other Non-current Liabilities | $116.0K | |
| Total Liabilities | $142M | |
| Common Stock | $33.0K | |
| Retained Earnings | $-676M | |
| AOCI | $106.0K | |
| Stockholders' Equity | $-616M | |
| Liabilities + Equity | $330M | |
| Shares Outstanding | 33,116,957 |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Revenue | $6M | $7M | $10M | $9M | |
| R&D Expense | $64M | $58M | $60M | $47M | |
| SG&A Expense | $14M | $14M | $11M | $10M | |
| Operating Expenses | $78M | $71M | $70M | $57M | |
| Operating Income | $-72M | $-64M | $-60M | $-48M | |
| Interest Income | $5M | $3M | $4M | $4M | |
| Other Non-op | $4M | $2M | $3M | $4M | |
| Pretax Income | $-67M | $-62M | $-57M | $-44M | |
| Income Tax | $53.0K | $28.0K | $44.0K | $56.0K | |
| Net Income | $-67M | $-61M | $-52M | $-42M | |
| EPS (Basic) | $-0.52 | $-1.07 | $-1.94 | $-1.62 | |
| EPS (Diluted) | $-0.52 | $-1.07 | $-1.94 | $-1.62 | |
| Shares (Basic) | 128,240,371 | 64,871,295 | 32,996,506 | 32,791,905 | |
| Shares (Diluted) | 128,240,371 | 64,871,295 | 32,996,506 | 32,791,905 | |
| EBITDA | $-72M | $-64M | · | · |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $135M | $161M | · | · | |
| Short-term Investments | $322M | $356M | · | · | |
| Prepaid Expense | $13M | $19M | · | · | |
| Current Assets | $470M | $535M | · | · | |
| PP&E (Net) | $27M | $28M | · | · | |
| PP&E (Gross) | $82M | $79M | · | · | |
| Accum. Depreciation | $55M | $52M | · | · | |
| Other Non-current Assets | $9M | $5M | · | · | |
| Total Assets | $562M | $626M | · | · | |
| Accounts Payable | $6M | $8M | · | · | |
| Current Liabilities | $57M | $58M | · | · | |
| Capital Leases | $48M | $49M | · | · | |
| Other Non-current Liabilities | $0 | $0 | · | · | |
| Total Liabilities | $106M | $111M | · | · | |
| Common Stock | $128.0K | $128.0K | · | · | |
| Retained Earnings | $-805M | $-738M | · | · | |
| AOCI | $-129.0K | $24.0K | · | · | |
| Stockholders' Equity | $456M | $515M | · | · | |
| Liabilities + Equity | $562M | $626M | · | · | |
| Shares Outstanding | 128,269,428 | 128,192,484 | · | · |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| D&A | $3M | $3M | $3M | $3M | |
| Stock-based Comp | $8M | $6M | $5M | $5M | |
| Operating Cash Flow | $-58M | $-80M | $-49M | $-53M | |
| CapEx | $933.0K | $4M | $154.0K | $751.0K | |
| Investing Cash Flow | $33M | $-260M | $-17M | $76M | |
| Financing Cash Flow | $-579.0K | $379M | $-263.0K | $21M | |
| Net Change in Cash | $-25M | $39M | $-66M | $43M | |
| Free Cash Flow | · | $-84M | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Operating Margin | -1134.2% | -887.5% | · | · | |
| Net Margin | -1065.2% | -850.6% | · | · | |
| Pretax Margin | -1064.3% | -853.9% | · | · | |
| EBITDA Margin | -1134.2% | -887.5% | · | · | |
| ROA | -23.9% | -19.6% | · | · | |
| ROE | -29.5% | -23.9% | · | · | |
| ROIC | -15.7% | -12.5% | · | · |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Current Ratio | 8.3 | 9.2 | · | · | |
| Quick Ratio | 8.1 | 8.8 | · | · |
Efficiency
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | · |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Book Value / Share | $3.56 | $4.02 | · | · | |
| Revenue / Share | $0.05 | $0.11 | · | · | |
| Cash Flow / Share | · | $-1.24 | · | · | |
| Cash / Share | $1.06 | $1.25 | · | · |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Market Cap | $2.16B | · | · | · | |
| P/B | 4.7 | · | · | · | |
| P / Tangible Book | 4.7 | · | · | · |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
No data for this statement
Not enough fundamentals data to build this statement yet.
No data for this statement
Not enough fundamentals data to build this statement yet.
No data for this statement
Not enough fundamentals data to build this statement yet.
Company insiders 13 insiders · 6 officers · 8 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Michael Nally | Chief Executive Officer | March 4, 2026 P | 572,707 | 1 | 0 | $240,000 |
| Jason Silvers | President & CFO | Feb. 26, 2026 A | 1,000 | 3 | 0 | $32,000 |
| Laurie Anne Lee | Chief Medical Officer | Feb. 26, 2026 A | · | 0 | 0 | $0 |
| Beth Grous | Chief People Officer | Feb. 26, 2026 A | 300 | 1 | 0 | $4,800 |
| Gevorg Grigoryan | Chief Technology Officer | Feb. 26, 2026 A | · | 0 | 0 | $0 |
| Sean Martin | Chief Legal Officer & GC | Feb. 26, 2026 A | · | 0 | 0 | $0 |
| Frances Arnold | Director | Sept. 1, 2026 S | 231,472 | 0 | 1 | $-16,000 |
| Stephane Bancel | Director | March 2, 2026 C | 724,160 | 0 | 0 | $0 |
| Paul Gray Parker | Director | Feb. 26, 2026 A | · | 0 | 0 | $0 |
| Rupert Vessey | Director | Feb. 26, 2026 A | · | 0 | 0 | $0 |
| Jane L Mendillo | Director | Feb. 26, 2026 A | 1,500 | 1 | 0 | $24,000 |
| Nancy A Simonian | Director | Feb. 26, 2026 A | · | 0 | 0 | $0 |
| Marsha Fanucci | Director | Feb. 26, 2026 A | · | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 10 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.02% | 18,122 SH | Aug. 19, 2026 | Daily |
| IWO · iShares Trust | 0.02% | 157,860 SH | Sept. 11, 2026 | Daily |
| IWM · iShares Trust | 0.01% | 621,969 SH | Sept. 11, 2026 | Daily |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.01% | 140,478 SH | Aug. 19, 2026 | Daily |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.01% | 6,607 SH | Aug. 19, 2026 | Daily |
| VXF · VANGUARD INDEX FUNDS | 0.00% | 296,479 SH | Aug. 19, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 816,876 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 2,078 SH | Aug. 19, 2026 | Daily |
| IWN · iShares Trust | · | 65,687 SH | Sept. 11, 2026 | Daily |
| ISCB · iShares Trust | · | 1,115 SH | Sept. 11, 2026 | Daily |
GENB Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 12 analysts
BUY
Median target
$27.00
+97.2%
3 25.0%
Strong Buy
8 66.7%
Buy
1 8.3%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
5 analysts · 2026-09-29Mean target $27.00 +97.2%
← Below all targets
Current price $13.69
Low$22.00
Mean$27.00
High$30.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| GENB | · | · | · | · | · | · |
| ABSI | $529M | -4.2 | -38.2% | -4113.7% | -63.5% | · |
| VIR | $841M | -1.9 | -7.6% | -638.9% | -51.1% | · |
| SRPT | $2.26B | -3.0 | 15.6% | -32.5% | -57.1% | · |
| NVAX | $1.09B | 2.6 | 64.7% | 39.2% | -977.1% | · |
| NTLA | $1.05B | -2.4 | 16.9% | -609.8% | -59.5% | · |
| STOK | $1.87B | -264.5 | 404.5% | -3.7% | -2.0% | · |
| ZYME | $1.97B | -24.4 | 38.9% | -76.6% | -26.9% | · |
| XNCR | $1.10B | -12.3 | 13.7% | -73.2% | -14.0% | · |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 6, 2026